Combination of Chartis system and Zephyr EBV treatment effective in treating emphysema

Pulmonx, an emerging leader in interventional pulmonology, announced today that the European Respiratory Journal has published the results of the Chartis Multi-Centre study. The study is the first to combine the Chartis Pulmonary Assessment System and Zephyr EBV treatment for patients with advanced emphysema. The published results of the study demonstrate that in patients who achieve volume reduction post Endobronchial Valve treatment, the majority get clinically significant responses in lung function, exercise tolerance and quality of life measures. After detailed review of the U.S. and European VENT data, a much broader profile of patient characteristics was identified for potential inclusion; including patients that would have been excluded in the previous studies.    

"Using the Chartis system to reliably plan EBV treatment can provide very real benefits for emphysema patients by relieving the hyperinflation and providing clinical benefit. This is a welcome advance for patients who have very few treatment options available to them" said Professor Felix Herth, MD, PhD., FCCP, Chairman and Head of Pneumology and Respiratory Care at Thoraxklinik, University of Heidelberg, Germany. "I believe that the publication of the results of the study will lead to Chartis and EBV treatment becoming a standard-of-care in the management of emphysema," he continued.    

Source: Pulmonx